Business · 30/08/1994Updated: 10/18/2026 · 1 min read
FDA Determines Regulatory Review Period for Zosyn Patent Extension
Summary
The Food and Drug Administration has officially confirmed the regulatory review period for Zosyn, a human drug product, as required by law, following a submission to the Commissioner of Patents and Trademarks for patent extension.
Original source language: Federal Register — Health and Human ServicesOpen original release →